Day: May 19, 2023

Xiao-I Launches Revolutionary Intelligent Document Processing Solution, Catalyzing the Future of Enterprise Document Management

Xiao-I Launches Revolutionary Intelligent Document Processing Solution, Catalyzing the Future of Enterprise Document Management

Written by Customer Service on . Posted in Public Companies.

SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) — Xiao-I Corporation (Nasdaq: AIXI) (“Xiao-I” or the “Company”), a leading cognitive artificial intelligence (“AI”) enterprise in China, today announced the launch of its state-of-the-art Intelligent Document Processing (“IDP”) product. This innovative solution is delivered by a smart and efficient platform that streamlines and automates the document management process, empowering businesses towards an era of intelligent operations. In the fast-paced landscape of digital transformation, enterprises frequently grapple with an overwhelming volume of documents, intricate document types, and inefficiency in manual information processing. Xiao-I’s IDP solution addresses these challenges by providing automated document recognition, classification, and key information extraction to...

Continue reading

Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo’s STAR Platform into the clinic

Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo’s STAR Platform into the clinic

Written by Customer Service on . Posted in Public Companies.

Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approach Ipsen to pay Marengo $45 million upfront with potential for additional milestone payments PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 01 August, 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics, Inc. today announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Under the terms of the agreement, Ipsen will make an upfront payment of $45 million, together with potential payments up to a total...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.